[{"question": "How long should a trial period of LTRA be given to children under 5 with suspected uncontrolled asthma?", "generated_answer": "According to the context, a trial period of 8 to 12 weeks should be given to children under 5 with suspected uncontrolled asthma, for the leukotriene receptor antagonist (LTRA) to be effective.", "true_answer": "8 to 12 weeks.", "relevant_docs": ["(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 23 of\n64 1.8.3 Consider incr easing t o paediatric moderat e-dose MART if ast hma is not \ncontr olled on paediatric lo w-dose MART . [BTS/NICE/SIGN 202 4] \nCon ventional pat hwa y \n1.8.4 Consider adding a leukotriene r ecept or antagonist  (LTRA) t o twice daily \npaediatric lo w-dose ICS plus SABA as needed when a child has uncontr olled \nasthma and is assessed as unable t o manage t he MART r egimen. G ive the LTRA \nfor a trial period of 8 t o 12 w eeks (unless t here are side eff ects), then st op it if it \nis ineff ectiv e. [BTS/NICE/SIGN 202 4] \nNovember 202 4: Follow the MHRA saf ety advice on t he risk of neur opsy chiatric \nreactions in people taking mont elukast . \n1.8.5 Offer a twice daily paediatric lo w-dose ICS/L ABA ( long-acting beta 2 agonist ) \ncombination inhaler plus SABA as needed t o childr en assessed as unable t o \nmanage t he MART r egimen if t heir ast hma is not contr olled on paediatric lo w-\ndose ICS plus SABA as needed (wit h or wit hout an L TRA depending on pr evious \nresponse). [BTS/NICE/SIGN 202 4] \n1.8.6 Offer a twice daily paediatric moderat e-dose ICS/L ABA inhaler plus SABA as \nneeded t o childr en wit h ast hma t hat is not contr olled on paediatric lo w-dose ICS/\nLABA plus SABA as needed (wit h or wit hout an L TRA depending on pr evious \nresponse). [BTS/NICE/SIGN 202 4] \nAll childr en aged 5 t o 11 \n1.8.7 Refer childr en to a specialist in ast hma car e if their ast hma is not contr olled on \npaediatric moderat e-dose MART or paediatric moderat e-dose ICS/L ABA \nmaint enance tr eatment (wit h or wit hout an L TRA, depending on pr evious \nresponse). [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 2 4 of\n64 For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on medicine \ncombination and sequencing in childr en aged 5 t o 11. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \ndrug combinations and sequencing f or ast hma management . \n1.9 P harmac ological manag emen t in childr en under \n5 \nThese r ecommendations ar e for childr en under  5 wit h newly suspect ed or confirmed \nasthma, or wit h ast hma sympt oms t hat ar e uncontr olled on t heir curr ent tr eatment. \nSee also algorit hm E f or a summar y of t he pharmacological management of ast hma in \nchildr en under 5 . \n1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \ncorticost eroid (ICS) as maint enance t herap y (wit h a shor t-acting beta 2 agonist \n[SABA] f or reliever therap y) in childr en under  5 wit h suspect ed ast hma and: \n\u2022 sympt oms at pr esentation t hat indicat e the need f or maint enance t herap y \n(for example, int erval sympt oms in childr en wit h anot her atopic disor der), or \n\u2022 severe acut e episodes of difficulty br eathing and wheez e (for example, \nrequiring hospital admission, or needing 2 or mor e courses of oral \ncorticost eroids). [BTS/NICE/SIGN 202 4] \n1.9.2 If sympt oms do not r esolv e during t he trial period, tak e the following sequential \nsteps: \n\u2022 check inhaler t echnique and adher ence \n\u2022 check whet her t here is an en vironmental sour ce of t heir sympt oms (f or \nexample mould in t he home, cold housing, smok ers or indoor air pollution) \n\u2022 review whet her an alt ernativ e diagnosis is lik ely. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 25 of\n64 If none of t hese e xplain t he failure to respond t o treatment, r efer the child t o \na specialist in ast hma car e. [BTS/NICE/SIGN 202 4] \n1.9.3 Consider st opping ICS and SABA tr eatment aft er 8 t o 12 weeks if sympt oms ar e \nresolv ed. R eview t he sympt oms aft er a fur ther 3 mont hs. [BTS/NICE/SIGN 202 4] \n1.9.4 If sympt oms r esolv e during t he trial period, but t hen: \n\u2022 sympt oms r ecur b y the 3-mont h review , or \n\u2022 the child has an acut e episode r equiring syst emic cor ticost eroids or \nhospitalisation, r estar t regular ICS (begin at a paediatric lo w dose and titrat e \nup to a paediatric moderat e dose if needed) wit h SABA as needed and \nconsider a fur ther trial wit hout tr eatment aft er reviewing t he child wit hin 12 \nmont hs. [BTS/NICE/SIGN 202 4] \n1.9.5 If suspect ed ast hma is uncontr olled in childr en under  5 on a paediatric moderat e \ndose of ICS as maint enance t herap y (wit h SABA as needed), consider a", "depar tment twice or mor e, because of wheezing or br eathlessness should be r eferred to a \nspecialist r espirat ory paediatrician f or advice on diagnosis and management. \nHow the r ecommenda tions mig ht affect practice \nThe diagnostic t ests recommended f or bot h childr en and adult s are not r outinely carried \nout in curr ent practice, wit h the exception of spir ometr y and r eversibility t esting, which is \nperformed in some adult s wit h suspect ed ast hma. F eNO equipment is not a vailable in \nsome ar eas, but an eosinophil count and IgE le vel is easily obtainable e verywher e. \nBronchial challenge t ests are not done in primar y car e and infr equent ly used in secondar y \ncare. The r ecommendations will incr ease t he demand f or challenge t ests and initially t here \nwill be a capacity pr oblem. Incorporating t he recommended diagnostic sequences int o \nclinical practice w ould t herefore requir e significant in vestment. Ho wever, using t he tests \nincreases t he accuracy of ast hma diagnosis and will be cost -effectiv e over time. \nThe r ecommendations f or childr en under 5 ar e based on a pragmatic trial of tr eatment, as \nis curr ent practice. \nReturn t o recommendations \nMonitoring asthma c ontrol \nRecommendations 1 .5.1 to 1.5.4 \nWhy the c ommi ttee made the r ecommenda tions \nThe committ ee agr eed t hat t here is some inf ormation t hat should alwa ys be obtained at a \nroutine monit oring r eview , for example whet her an y courses of oral cor ticost eroid ha ve \nbeen needed since t he last r eview . \nSympt om questionnair es and diaries \nThe committ ee look ed at e vidence on t he eff ects of monit oring ast hma contr ol using \nsympt om questionnair es giv en at int ervals ranging fr om w eekly t o twice in 3 mont hs. \nAlthough t here were a small number of beneficial out comes in individual studies, o verall, Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 47 of\n64 there was no clinically useful eff ect of t he monit oring in eit her adult s or childr en. The \ncommitt ee not ed that t he int erventions w ere comple x, as t hey assessed t he eff ects not \njust of t he sympt om monit oring but also t he therapeutic adjustment s made in r esponse t o \nthe questionnair e result. Nonet heless, t hey concluded t hat t hey should not r ecommend \nquestionnair es used at t hese r elativ ely fr equent int ervals. \nThe committ ee w ere awar e of e vidence (t hat was not par t of t his review) sho wing t hat t he \nresult s of ast hma contr ol questionnair es pr edict t he risk of futur e ast hma attacks. The y \ntherefore used t heir e xperience t o recommend t hat questionnair es should be used as par t \nof an y ast hma-r elated review . For most people t his will be t heir annual r eview . \nPulmonar y function \nThe committ ee look ed for evidence on t he use of spir ometr y and PEF monit oring as \nmeasur es of ast hma contr ol but did not find an y data on spir ometr y used in t his cont ext. \nTher e was e vidence on PEF monit oring in bot h adult s and childr en. The monit oring was \ntypically link ed to treatment changes trigger ed by designat ed thresholds of PEF and \ncompar ed wit h the eff ects of tr eatment changes trigger ed by sympt oms. In adult s, regular \nPEF measur ement was associat ed wit h worse quality-of -life paramet ers. The committ ee \nthought t hat t his might be e xplained b y regular monit oring inducing anxiety in some \npeople if PEF is not consist ently high, and b y the incon venience of making r egular \nmeasur ement s. \nIn bot h adult s and childr en, PEF monit oring was associat ed wit h an incr ease in ast hma \nattacks, which appears t o be a fur ther disadv antage of r egular monit oring. The committ ee \nfound t his har d to explain as monit oring it self seems unlik ely to mak e ast hma w orse. It is \npossible t hat PEF measur ement s ma y have led t o quick er identification and appr opriat e \nearly tr eatment of some attacks. Ho wever, if this is t he case, one might e xpect t o see a \nreduction in t he need f or hospitalisation, or time off w ork or school, and t hese pot ential \nbenefit s were not seen. \nThe committ ee agr eed t hat a minority of people wit h ast hma benefit fr om regular \nmeasur ement of PEF , for example t hose who ar e poor at per ceiving changes in t heir \nairways and ar e therefore at risk of dela ying tr eatment of ast hma attacks. The y also t ook \ninto account e vidence in adult s that was not par t of t he formal r eview sho wing t hat action \nplans t hat incorporat e PEF measur ement can be beneficial. So, t hey recommended against \nthe use of r outine PEF monit oring, wit h the ca veat t hat it might ha ve value in some Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided is completely correct, accurate, and factual. It aligns perfectly with the reference answer, which states that a trial period for LTRA should be 8 to 12 weeks for children under 5 with suspected uncontrolled asthma. The response includes the same time frame and is specific to the population in question, which is children under 5. Therefore, it meets the highest standard set by the score rubric."}, {"question": "What organization provides guidelines for hypertension diagnosis and management in adults?", "generated_answer": "The organization that provides guidelines for hypertension diagnosis and management in adults is NICE (National Institute for Health and Care Excellence).", "true_answer": "NICE (National Institute for Health and Care Excellence).", "relevant_docs": ["1.4.13 Consider antih yper tensiv e drug tr eatment in addition t o lifestyle advice f or \npeople aged o ver 80 wit h stage  1 hyper tension if t heir clinic blood pr essur e is \nover 150/90  mmHg. Use clinical judgement f or people wit h frailty or \nmultimorbidity (see also NICE's guideline on multimorbidity ). [2019] \n1.4.14 For adult s aged under  40 wit h hyper tension, consider seeking specialist \nevaluation of secondar y causes of h yper tension and a mor e detailed assessment \nof the long-t erm balance of tr eatment benefit and risks. [2019] \nFor a shor t explanation of wh y the committ ee made t he 2019 r ecommendations and \nhow they might aff ect practice, see t he rationale and impact section on star ting \nantih yper tensiv e drug tr eatment . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview C: \ninitiating tr eatment . \nMonitoring tr eatmen t and b lood pr essur e tar gets \nFor specific r ecommendations on blood pr essur e contr ol in people wit h other conditions or \nwho ar e pregnant, see NICE's guidelines on chr onic kidne y disease , type 1 diabet es and \nhyper tension in pr egnancy . \nSee also table 1 f or clinic blood pr essur e tar gets for people aged under 80 and table 2 f or \nclinic blood pr essur e tar gets for people aged 80 and o ver. The tables co ver people wit h \nhyper tension (wit h or wit hout type 2 diabet es) as w ell as people wit h chr onic kidne y \ndisease or type 1 diabet es. Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 13 of\n52 Table 1: Clinic blood pr essur e tar gets for people aged under 80 \nPerson under 80 wit h: Clinic blood \npressur e \ntarget Sour ce \n\u2022 hyper tension (wit h or wit hout type 2 \ndiabet es) or \n\u2022 type 1 diabet es plus albumin t o \ncreatinine ratio less t han 7 0 mg/mmol \nor \n\u2022 chronic kidne y disease plus albumin \nto creatinine ratio less t han 7 0 mg/\nmmol Below \n140/90 Recommendation 1 .4.20 \nNICE's guideline on type 1 \ndiabet es in adult s \n(recommendation 1 .13.8) \nNICE's guideline on chr onic kidne y \ndisease  (recommendation 1 .6.1) \n\u2022 type 1 diabet es plus albumin t o \ncreatinine ratio of 7 0 mg/mmol or \nmore or \n\u2022 chronic kidne y disease plus albumin \nto creatinine ratio of 7 0 mg/mmol or \nmore Below \n130/80 NICE's guideline on type 1 \ndiabet es in adult s \n(recommendation 1 .13.8) \nNICE's guideline on chr onic kidne y \ndisease  (recommendation 1 .6.2) \nTable 2: Clinic blood pr essur e tar gets for people aged 80 and o ver \nPerson aged 80 and o ver wit h: Clinic blood \npressur e \ntarget Sour ce \n\u2022 hyper tension (wit h or wit hout type 2 \ndiabet es) or \n\u2022 type 1 diabet es (regar dless of \nalbumin t o creatinine ratio ) Below \n150/90 Recommendation 1 .4.21 \nNICE's guideline on type 1 \ndiabet es in adult s \n(recommendation 1 .13.8) \n\u2022 chronic kidne y disease plus albumin \nto creatinine ratio less t han 7 0 mg/\nmmol Below \n140/90 NICE's guideline on chr onic kidne y \ndisease  (recommendation 1 .6.1) Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 14 of\n52 \u2022 chronic kidne y disease plus albumin \nto creatinine ratio of 7 0 mg/mmol or \nmore Below \n130/80 NICE's guideline on chr onic kidne y \ndisease  (recommendation 1 .6.2) \n1.4.15 Use clinic blood pr essur e measur ement s to monit or the response t o lifestyle \nchanges or drug tr eatment in people wit h hyper tension. [2019] \n1.4.16 Check f or postural h ypot ension (see recommendation 1 .1.5) in people wit h \nhyper tension and: \n\u2022 type  2 diabet es or \n\u2022 sympt oms of postural h ypot ension (see also r ecommendation 1 .1.7) or \n\u2022 aged 80  and o ver. \nIn people wit h a significant postural dr op or sympt oms of postural \nhypot ension, tr eat t o a blood pr essur e tar get based on standing blood \npressur e. [2019 , amended 2023] \n1.4.17 Advise people wit h hyper tension who choose t o self -monit or their blood pr essur e \nto use HBPM. ( NHS England is suppor ting t he use of HBPM t hrough t he blood \npressur e@home scheme .) [2019] \n1.4.18 Consider ABPM or HBPM, in addition t o clinic blood pr essur e measur ement s, for \npeople wit h hyper tension identified as ha ving a white-coat eff ect or mask ed \nhyper tension  (in which clinic and non-clinic blood pr essur e result s are \nconflicting). Be awar e that t he corr esponding measur ement s for ABPM and HBPM \nare 5 mmHg lo wer than f or clinic measur ement s (see recommendation  1.2.8 for \ndiagnostic t hresholds ). [2019] \n1.4.19 For people who choose t o use HBPM, pr ovide: \n\u2022 training and advice on using home blood pr essur e monit ors \n\u2022 information about what t o do if t hey are not achie ving t heir tar get blood \npressur e. Hyper tension in adult s: diagnosis and management (NG136)", "\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 10 of\n52 1.4.3 Ask about people's alcohol consumption and encourage a r educed intak e if t hey \ndrink e xcessiv ely, because t his can r educe blood pr essur e and has br oader \nhealt h benefit s. See t he recommendations f or practice in NICE's guideline on \nalcohol-use disor ders. [2004 , amended 2019] \n1.4.4 Discourage e xcessiv e consumption of coff ee and ot her caff eine-rich pr oduct s. \n[2004] \n1.4.5 Encourage people t o keep t heir dietar y sodium intak e low, either b y reducing or \nsubstituting sodium salt, as t his can r educe blood pr essur e. Not e that salt \nsubstitut es containing potassium chloride should not be used b y older people, \npeople wit h diabet es, pr egnant w omen, people wit h kidne y disease and people \ntaking some antih yper tensiv e drugs, such as A CE inhibit ors and angiot ensin  II \nrecept or block ers. Encourage salt r eduction in t hese gr oups. [2004 , amended \n2019] \n1.4.6 Do not off er calcium, magnesium or potassium supplement s as a met hod f or \nreducing blood pr essur e. [2004] \n1.4.7 Offer advice and help t o smok ers t o stop smoking. See NICE's guideline on \ntobacco . [2004] \n1.4.8 Inform people about local initiativ es by, for example, healt hcare teams or patient \norganisations t hat pr ovide suppor t and pr omot e healt hy lifestyle change, \nespecially t hose t hat include gr oup w ork f or motiv ating lif estyle change. [2004] \nFor a shor t explanation of wh y the committ ee delet ed the recommendation on \nrelaxation t herapies and ho w this might aff ect practice, see t he rationale and impact \nsection on r elaxation t herapies . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview H: \nrelaxation t herapies . \nStarting an tihyper tensi ve drug tr eatmen t \nNICE has pr oduced a patient decision aid on tr eatment options f or hyper tension  to help \npeople and t heir healt hcare professionals discuss t he diff erent types of tr eatment and Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 11 of\n52 make a decision t hat is right f or each person. \nFor advice on shar ed decision making f or medicines, see t he inf ormation on patient \ndecision aids in NICE's guideline on medicines optimisation . \nTo suppor t adher ence and ensur e that people wit h hyper tension mak e the most eff ectiv e \nuse of t heir medicines, see NICE's guideline on medicines adher ence . \n1.4.9 Offer antih yper tensiv e drug tr eatment in addition t o lifestyle advice t o adult s of \nany age wit h persist ent stage  2 hyper tension . Use clinical judgement f or people \nof an y age wit h frailty or multimorbidity (see also NICE's guideline on \nmultimorbidity ). [2019] \n1.4.10 Discuss star ting antih yper tensiv e drug tr eatment, in addition t o lifestyle advice, \nwith adult s aged under  80 wit h persist ent stage  1 hyper tension  who ha ve 1 or \nmore of t he following: \n\u2022 target or gan damage \n\u2022 established car diovascular disease \n\u2022 renal disease \n\u2022 diabet es \n\u2022 an estimat ed 10-y ear risk of car diovascular disease of 10% or mor e. \nUse clinical judgement f or people wit h frailty or multimorbidity (see also \nNICE's guideline on multimorbidity ). [2019] \n1.4.11 Discuss wit h the person t heir individual car diovascular disease risk and t heir \npreferences f or treatment, including no tr eatment, and e xplain t he risks and \nbenefit s bef ore star ting antih yper tensiv e drug tr eatment. Continue t o off er \nlifestyle advice and suppor t them t o mak e lifestyle changes (see t he section on \nlifestyle int erventions ), whet her or not t hey choose t o star t antih yper tensiv e drug \ntreatment. [2019] \n1.4.12 Consider antih yper tensiv e drug tr eatment in addition t o lifestyle advice f or adult s \naged under  60 wit h stage  1 hyper tension and an estimat ed 10-y ear risk belo w Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 12 of\n52 10%. Bear in mind t hat 10-y ear car diovascular risk ma y under estimat e the lif etime \nprobability of de veloping car diovascular disease. [2019] \n1.4.13 Consider antih yper tensiv e drug tr eatment in addition t o lifestyle advice f or \npeople aged o ver 80 wit h stage  1 hyper tension if t heir clinic blood pr essur e is \nover 150/90  mmHg. Use clinical judgement f or people wit h frailty or \nmultimorbidity (see also NICE's guideline on multimorbidity ). [2019] \n1.4.14 For adult s aged under  40 wit h hyper tension, consider seeking specialist \nevaluation of secondar y causes of h yper tension and a mor e detailed assessment"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided correctly identifies NICE (National Institute for Health and Care Excellence) as the organization that provides guidelines for hypertension diagnosis and management in adults. This matches the reference answer exactly, indicating that the response is completely correct, accurate, and factual."}, {"question": "Which group of people should not use salt substitutes containing potassium chloride?", "generated_answer": "People with kidney disease should not use salt substitutes containing potassium chloride.", "true_answer": "Older people, people with diabetes, pregnant women, people with kidney disease, and people taking some antihypertensive drugs, such as ACE inhibitors and angiotensin II receptor blockers.", "relevant_docs": ["\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 10 of\n52 1.4.3 Ask about people's alcohol consumption and encourage a r educed intak e if t hey \ndrink e xcessiv ely, because t his can r educe blood pr essur e and has br oader \nhealt h benefit s. See t he recommendations f or practice in NICE's guideline on \nalcohol-use disor ders. [2004 , amended 2019] \n1.4.4 Discourage e xcessiv e consumption of coff ee and ot her caff eine-rich pr oduct s. \n[2004] \n1.4.5 Encourage people t o keep t heir dietar y sodium intak e low, either b y reducing or \nsubstituting sodium salt, as t his can r educe blood pr essur e. Not e that salt \nsubstitut es containing potassium chloride should not be used b y older people, \npeople wit h diabet es, pr egnant w omen, people wit h kidne y disease and people \ntaking some antih yper tensiv e drugs, such as A CE inhibit ors and angiot ensin  II \nrecept or block ers. Encourage salt r eduction in t hese gr oups. [2004 , amended \n2019] \n1.4.6 Do not off er calcium, magnesium or potassium supplement s as a met hod f or \nreducing blood pr essur e. [2004] \n1.4.7 Offer advice and help t o smok ers t o stop smoking. See NICE's guideline on \ntobacco . [2004] \n1.4.8 Inform people about local initiativ es by, for example, healt hcare teams or patient \norganisations t hat pr ovide suppor t and pr omot e healt hy lifestyle change, \nespecially t hose t hat include gr oup w ork f or motiv ating lif estyle change. [2004] \nFor a shor t explanation of wh y the committ ee delet ed the recommendation on \nrelaxation t herapies and ho w this might aff ect practice, see t he rationale and impact \nsection on r elaxation t herapies . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview H: \nrelaxation t herapies . \nStarting an tihyper tensi ve drug tr eatmen t \nNICE has pr oduced a patient decision aid on tr eatment options f or hyper tension  to help \npeople and t heir healt hcare professionals discuss t he diff erent types of tr eatment and Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 11 of\n52 make a decision t hat is right f or each person. \nFor advice on shar ed decision making f or medicines, see t he inf ormation on patient \ndecision aids in NICE's guideline on medicines optimisation . \nTo suppor t adher ence and ensur e that people wit h hyper tension mak e the most eff ectiv e \nuse of t heir medicines, see NICE's guideline on medicines adher ence . \n1.4.9 Offer antih yper tensiv e drug tr eatment in addition t o lifestyle advice t o adult s of \nany age wit h persist ent stage  2 hyper tension . Use clinical judgement f or people \nof an y age wit h frailty or multimorbidity (see also NICE's guideline on \nmultimorbidity ). [2019] \n1.4.10 Discuss star ting antih yper tensiv e drug tr eatment, in addition t o lifestyle advice, \nwith adult s aged under  80 wit h persist ent stage  1 hyper tension  who ha ve 1 or \nmore of t he following: \n\u2022 target or gan damage \n\u2022 established car diovascular disease \n\u2022 renal disease \n\u2022 diabet es \n\u2022 an estimat ed 10-y ear risk of car diovascular disease of 10% or mor e. \nUse clinical judgement f or people wit h frailty or multimorbidity (see also \nNICE's guideline on multimorbidity ). [2019] \n1.4.11 Discuss wit h the person t heir individual car diovascular disease risk and t heir \npreferences f or treatment, including no tr eatment, and e xplain t he risks and \nbenefit s bef ore star ting antih yper tensiv e drug tr eatment. Continue t o off er \nlifestyle advice and suppor t them t o mak e lifestyle changes (see t he section on \nlifestyle int erventions ), whet her or not t hey choose t o star t antih yper tensiv e drug \ntreatment. [2019] \n1.4.12 Consider antih yper tensiv e drug tr eatment in addition t o lifestyle advice f or adult s \naged under  60 wit h stage  1 hyper tension and an estimat ed 10-y ear risk belo w Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 12 of\n52 10%. Bear in mind t hat 10-y ear car diovascular risk ma y under estimat e the lif etime \nprobability of de veloping car diovascular disease. [2019] \n1.4.13 Consider antih yper tensiv e drug tr eatment in addition t o lifestyle advice f or \npeople aged o ver 80 wit h stage  1 hyper tension if t heir clinic blood pr essur e is \nover 150/90  mmHg. Use clinical judgement f or people wit h frailty or \nmultimorbidity (see also NICE's guideline on multimorbidity ). [2019] \n1.4.14 For adult s aged under  40 wit h hyper tension, consider seeking specialist \nevaluation of secondar y causes of h yper tension and a mor e detailed assessment", "hospitalisation, r estar t regular ICS (begin at a paediatric lo w dose and titrat e \nup to a paediatric moderat e dose if needed) wit h SABA as needed and \nconsider a fur ther trial wit hout tr eatment aft er reviewing t he child wit hin 12 \nmont hs. [BTS/NICE/SIGN 202 4] \n1.9.5 If suspect ed ast hma is uncontr olled in childr en under  5 on a paediatric moderat e \ndose of ICS as maint enance t herap y (wit h SABA as needed), consider a \nleukotriene r ecept or antagonist  (LTRA) in addition t o the ICS.  Give the LTRA f or a \ntrial period of 8 t o 12 w eeks (unless t here are side eff ects), then st op it if it is \nineffectiv e. [BTS/NICE/SIGN 202 4] \nNovember 202 4: Follow the MHRA saf ety advice on t he risk of neur opsy chiatric \nreactions in people taking mont elukast . \n1.9.6 If suspect ed ast hma is uncontr olled in childr en under  5 on a paediatric moderat e \ndose of ICS as maint enance t herap y and a trial of an L TRA has been unsuccessful \nor not t olerat ed, st op the LTRA and r efer the child t o a specialist in ast hma car e \nfor fur ther in vestigation and management.  [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on pharmacological \nmanagement in childr en under 5 . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 26 of\n64 1.10 De creasing main tenanc e ther apy \n1.10.1 At annual r eview discuss wit h the person wit h ast hma ( or their f amily or car er, if \nappr opriat e) the pot ential risks and benefit s of decr easing t heir maint enance \ntherap y when t heir ast hma has been w ell contr olled on t heir curr ent maint enance \ntherap y. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.10.2 When decr easing maint enance t herap y: \n\u2022 Stop or r educe dose of medicines in an or der t hat tak es int o account t he \nclinical eff ectiv eness when intr oduced, side eff ects and t he person's \npreference. \n\u2022 Allow at least 8 t o 12 w eeks bef ore considering a fur ther tr eatment r eduction. \n\u2022 If considering st ep-do wn tr eatment f or people aged 12 and o ver who ar e \nusing lo w-dose maint enance inhaled cor ticost eroid (ICS) plus a shor t-acting \nbeta 2 agonist (SABA) as needed or lo w-dose MART ( maint enance and \nreliever therap y), step do wn to low-dose ICS/f ormot erol combination inhaler \nas needed (as-needed AIR t herap y). [NICE 2017 , BTS/SIGN 2019 , amended \nBTS/NICE/SIGN 202 4] \n1.10.3 Agree wit h the person ( or their f amily or car er if appr opriat e) ho w the eff ects of \ndecr easing maint enance t herap y will be monit ored and r eview ed, including self -\nmonit oring and f ollow-up wit h a healt hcare professional. [NICE 2017] \n1.10.4 Review and updat e the person's ast hma action plan when decr easing \nmaint enance t herap y. [NICE 2017] \n1.11 A dher ence \n1.11.1 Check adher ence, using pr escription r ecords, and inhaler t echnique at e very \nasthma-r elated healt hcare review . Use t he principles out lined in t he NICE \nguidelines on shar ed decision making  (endorsed b y SIGN f or use in Scot land) and \nmedicines adher ence . [NICE 2017 , BTS/SIGN 2019] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 27 of\n64 1.12 A sthma in pr egnanc y and br eastfeeding \nFor recommendations on intrapar tum car e, see t he NICE guideline on intrapar tum car e for \nwomen wit h existing medical conditions or obst etric complications and t heir babies . \nPregnanc y \n1.12.1 People wit h ast hma should ha ve an ast hma r eview during early pr egnancy and in \nthe postpar tum period. Emphasise t he impor tance and saf ety of maintaining \ngood contr ol of ast hma during pr egnancy and of continuing ast hma medicines t o \navoid pr oblems f or themselv es and t heir bab y. [BTS/SIGN 2019] \n1.12.2 Advise an yone who is pr egnant and who smok es about t he dangers f or \nthemselv es and t heir babies and giv e appr opriat e suppor t to stop smoking. See \nthe NICE guideline on t obacco  for mor e information. [BTS/SIGN 2019] \n1.12.3 Advise using t he following medicines as normal during pr egnancy: \n\u2022 shor t-acting and long-acting beta 2 agonist s \n\u2022 inhaled cor ticost eroids \n\u2022 oral t heoph yllines. [BTS/SIGN 2019] \n1.12.4 Offer oral cor ticost eroids during pr egnancy if needed t o treat e xacerbations of \nasthma. Advise t hat t he benefit s of tr eatment wit h oral cor ticost eroids outw eigh \nthe risks. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4]"], "eval_score_GPT4": "3", "eval_feedback_GPT4": "Feedback: The response correctly identifies people with kidney disease as a group that should not use salt substitutes containing potassium chloride. This is in line with the reference answer, which also lists people with kidney disease among others. However, the response does not mention other groups listed in the reference answer, such as older people, people with diabetes, pregnant women, and people taking certain antihypertensive drugs. Therefore, the response is somewhat correct but not complete."}, {"question": "What is accelerated hypertension also known as?", "generated_answer": "According to the context, accelerated hypertension is also known as \"malignant hypertension\".", "true_answer": "Malignant hypertension.", "relevant_docs": ["Accelerated hyper tension \nA severe incr ease in blood pr essur e to 180/120  mmHg or higher (and oft en over 220/\n120 mmHg) wit h signs of r etinal haemorrhage and/or papilloedema (sw elling of t he optic \nnerve). It is usually associat ed wit h new or pr ogressiv e tar get or gan damage and is also \nknown as malignant h yper tension. \nEstab lishe d cardiovascular dise ase \nMedical hist ory of ischaemic hear t disease, cer ebrovascular disease, peripheral v ascular \ndisease, aor tic aneur ysm or hear t failure. Car diovascular disease is a general t erm f or \nconditions aff ecting t he hear t or blood v essels. It is usually associat ed wit h a build-up of \nfatty deposit s inside t he ar teries (at heroscler osis) and an incr eased risk of blood clot s. It \ncan also be associat ed wit h damage t o arteries in or gans such as t he brain, hear t, kidne ys \nand e yes through deposition of glassy mat erial wit hin the ar tery walls (ar terioscler osis). \nCardiovascular disease is 1 of t he main causes of deat h and disability in t he UK, but it can \noften lar gely be pr evented by leading a healt hy lifestyle. \nMasked hyper tension \nClinic blood pr essur e measur ement s are normal (less t han 140/90  mmHg), but blood \npressur e measur ement s are higher when tak en out side t he clinic using a verage da ytime \nambulat ory blood pr essur e monit oring (ABPM) or a verage home blood pr essur e monit oring \n(HBPM) blood pr essur e measur ement s. \nPersisten t hyper tension \nHigh blood pr essur e at r epeat ed clinical encount ers. \nStage 1 hyper tension \nClinic blood pr essur e ranging fr om 140/90  mmHg t o 159/99  mmHg and subsequent ABPM Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 25 of\n52 daytime a verage or HBPM a verage blood pr essur e ranging fr om 135/85  mmHg t o 149/\n94 mmHg. \nStage 2 hyper tension \nClinic blood pr essur e of 160/100  mmHg or higher but less t han 180/120  mmHg and \nsubsequent ABPM da ytime a verage or HBPM a verage blood pr essur e of 150/95  mmHg or \nhigher . \nStage 3 or se vere hyper tension \nClinic syst olic blood pr essur e of 180  mmHg or higher or clinic diast olic blood pr essur e of \n120 mmHg or higher . \nTarget organ damag e \nDamage t o organs such as t he hear t, brain, kidne ys and e yes. Examples ar e left v entricular \nhyper trophy, chronic kidne y disease, h yper tensiv e retinopat hy or incr eased urine \nalbumin:cr eatinine ratio. \nWhite-coat effect \nA discr epancy of mor e than 20/10  mmHg betw een clinic and a verage da ytime ABPM or \naverage HBPM blood pr essur e measur ement s at t he time of diagnosis. Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 26 of\n52 Recommenda tions f or research \nThe 2019 and 2022 guideline committ ees ha ve made t he following r ecommendations f or \nresear ch. \nKey recommenda tions f or research \n1 Automa ted blood pr essur e moni toring in pe ople wi th atrial \nfibrilla tion \nWhich aut omat ed blood pr essur e monit ors ar e suitable f or people wit h hyper tension and \natrial fibrillation? [2019] \nFor a shor t explanation of wh y the committ ee made t he recommendation f or resear ch, \nsee t he rationale on monit oring tr eatment and blood pr essur e tar gets for people \nwithout car diovascular disease . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview B: \nmonit oring t he response t o treatment . \n2 Thr esho lds f or in terventions in adul ts ag ed under  40 \nIn adult s aged under  40 wit h hyper tension (wit h or wit hout type  2 diabet es), what ar e the \nappr opriat e risk and blood pr essur e thresholds f or star ting tr eatment? [2019] \nFor a shor t explanation of wh y the committ ee made t he recommendation f or resear ch, \nsee t he rationale on star ting antih yper tensiv e drug tr eatment . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview C: \ninitiating tr eatment . Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 27 of\n52 3 Blood pr essur e tar gets for pe ople ag ed over 80 \nWhat is t he optimum blood pr essur e tar get f or people aged o ver 80 wit h treated primar y \nhyper tension (wit h or wit hout car diovascular disease)? [2022] \nFor a shor t explanation of wh y the committ ee made t he recommendation f or resear ch, \nsee t he rationale on blood pr essur e tar gets for people wit h car diovascular disease . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview D: \ntargets. \n4 Step 1 tr eatmen t", "evidence f or this and agr eed t hat it was sufficient t o suppor t and r etain t his \nrecommendation. The committ ee agr eed it should be br oadened t o include t he choice of \nan ACE inhibit or or an angiot ensin  II recept or block er (ARB; also r eferred to as A-type \ndrugs), because t hey are now cost equiv alent, and t he committ ee also agr eed t hey are \nclinically equiv alent. \nFor people of Black African or African\u2013Caribbean f amily origin wit h type  2 diabet es, the \nprevious r ecommendation was t o off er st ep 1 dual t herap y wit h an A CE inhibit or and eit her \na diur etic (D-type drug) or a calcium channel block er (CCB; C-type drug). Ho wever, these \nrecommendations w ere based on monot herap y studies and when t he committ ee look ed at \nthis e vidence alongside t he new dual t herap y evidence r eview , they concluded t hat it was \ninsufficient t o recommend star ting dual t herap y in an y subgr oup of people wit h type  2 \ndiabet es. The committ ee not ed that people wit h type  2 diabet es who ar e older or ar e of \nBlack African or African\u2013Caribbean f amily origin ma y not achie ve their tar get blood \npressur e on A CE inhibit or or ARB monot herap y and ma y need t o star t step 2 drug t herap y \nin the shor t term. \nHow the r ecommenda tions mig ht affect practice \nOverall, t he recommendations f or st ep 1 treatment r eflect curr ent practice f or people who \ndo not ha ve type  2 diabet es. F or people of Black African or African\u2013Caribbean f amily origin \nwho ha ve type  2 diabet es, the recommendation t o star t antih yper tensiv e monot herap y \nrather t han dual t herap y ma y result in an e xtra clinical appointment if t he dose needs t o be \nadjust ed. Ho wever, it ma y also r educe pot ential harms fr om initial o vertreatment of blood \npressur e. \nReturn t o recommendations \nStep 2 and 3 tr eatmen t \nRecommendations 1 .4.40 t o 1.4.45 \nWhy the c ommi ttee made the r ecommenda tions \nNo e vidence f or st ep 2 or st ep 3 treatment was identified t hat was r elevant t o det ermining \nthe best sequence f or st ep 2 and st ep 3 antih yper tensiv e treatment. Some of t he studies Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 43 of\n52 available on drug tr eatment s for hyper tension w ere not included in t his review because \nthey were designed t o inform st ep 1 treatment. Ot hers did not r eflect UK clinical practice. \nFor details of t hese studies see evidence r eview F: st ep 2 and st ep 3 treatment . \nBased on e vidence fr om t he pr evious v ersion of t he guideline and t heir clinical e xper tise, \nthe committ ee members agr eed t o retain t he same choice of drugs fr om t he 2011 \nguideline, which r eflect curr ent best practice. The committ ee agr eed t hat, in t he absence \nof evidence of which tr eatment(s) ar e most eff ectiv e for st ep 2 or st ep 3, the \nrecommendation should be t o off er an y of t hese tr eatment s based on an individualised \nappr oach inf ormed b y risks and benefit s of each tr eatment and t he person wit h \nhyper tension's pr eference. \nThe committ ee not ed that t he changes t o the st ep 1 recommendations f or some people \nwith type  2 diabet es do not necessitat e a change in t he st ep 2 recommendations since t he \nsame options f or combination tr eatment at st ep 2 are available. \nThe committ ee agr eed t hat t he choice of drug should be discussed and agr eed wit h the \nperson, based on t he person's st ep 1 treatment, t he risks and benefit s of each tr eatment \noption, and taking int o account t he person's pr eferences and ot her clinical f actors. The \nupdat ed recommendations r eflect t his, giving t he choice of possible tr eatment options. A \nNICE patient decision aid on tr eatment choices f or high blood pr essur e has been \ndeveloped t o suppor t healt hcare professionals and people wit h hyper tension t o discuss \ntheir tr eatment options and mak e informed decisions. \nHow the r ecommenda tions mig ht affect practice \nThe r ecommendations ar e unlik ely to alter curr ent practice. The options f or drug tr eatment \nremain t he same and most st ep 2 or 3 tr eatment decisions ar e already based on an \nindividualised appr oach. \nReturn t o recommendations \nStep 4 tr eatmen t \nRecommendations 1 .4.46 t o 1.4.52 Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 44 of\n52 Why the c ommi ttee made the r ecommenda tions \nNo e vidence on st ep 4 treatment was identified t hat could be used t o formulat e new \nrecommendations. Ho wever, the committ ee review ed the 2011 r ecommendations and \nagreed t hat t hey should be r etained and updat ed to reflect curr ent best practice."], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided correctly identifies \"malignant hypertension\" as another term for accelerated hypertension. This matches the reference answer exactly, indicating that the response is completely correct, accurate, and factual."}, {"question": "Are digital inhalers recommended for routine use in asthma management by the NHS?", "generated_answer": "No, digital inhalers are not recommended for routine use in asthma management by the NHS. According to the context, the committee concluded that digital inhalers are not a cost-effective option for routine use in asthma, and they are only potentially valuable in selected people with asthma, such as those in whom the need for biologic therapy is being considered and there is a need to confirm good adherence.", "true_answer": "No, digital inhalers are not recommended for routine use in asthma management by the NHS.", "relevant_docs": ["further. The r eplacement t herapies in adult s and childr en ar e mor e expensiv e, but t hey \nshould pr oduce clinical benefit s and cost sa vings t hrough a r eduction in e xacerbations. \nReturn t o recommendations \nDigital inhaler s \nRecommendation 1 .6.10 \nWhy the c ommi ttee made the r ecommenda tion \nThe committ ee look ed at e vidence comparing t he use of digital smar t inhalers wit h usual \ncare and wit h digital inhalers wit h the feedback utility swit ched off . The trials included \nboth childr en and adult s wit h ast hma, and a v ariety of types of inhaler . The e vidence Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 50 of\n64 showed impr ovement in adher ence t o treatment wit h digital inhalers, but t his did not r esult \nin significant impr ovement in measur es of ast hma contr ol. In addition, t here was an \nunexplained incr ease in hospital admissions among people using digital inhalers when \ncompar ed wit h usual car e. The par ticipant s in t he contributing trials v aried considerably in \nterms of baseline adher ence and ast hma contr ol, and benefit was generally mor e likely in \nthe studies of people wit h poor er baseline v alues. \nDigital inhalers ar e mor e expensiv e than con ventional de vices, par tly because of t he \ndevice it self and par tly because of t he set -up and monit oring r equir ement s. The \ncommitt ee concluded t hat digital inhalers ar e not a cost -effectiv e option f or routine use in \nasthma. Ho wever, they are pot entially v aluable in select ed people wit h ast hma, f or \nexample t hose in whom t he need f or biologic t herap y is being consider ed and t here is a \nneed t o confirm good adher ence. Further r esear ch is needed t o identify mor e precisely t he \npeople and t he cir cumstances in which t hey might be used . \nHow the r ecommenda tion mig ht affect practice \nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \ncurrent practice. \nReturn t o recommendations \nMedicines f or the ini tial manag emen t of newly \ndiagnose d asthma in pe ople ag ed 12 and o ver \nRecommendations 1 .7.1 and 1 .7.2 \nWhy the c ommi ttee made the r ecommenda tions \nThe committ ee look ed at e vidence comparing 3 tr eatment options in people aged 12 and \nover wit h a new diagnosis of ast hma. These w ere SABA as needed wit h no ICS; r egular \nlow-dose ICS plus SABA as needed; and a combination inhaler of an ICS (budesonide) plus \nformot erol, a f ast onset long-acting beta 2 agonist (L ABA), used as needed (as-needed \nAIR). \nThe most impor tant diff erence betw een t he gr oups was a r eduction in se vere \nexacerbations of ast hma in t he gr oup using as-needed AIR t herap y, and t his applied t o the Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 51 of\n64 comparisons wit h bot h of t he ot her tr eatment options. Ther e were also f ewer \nexacerbations wit h ICS plus SABA t han wit h SABA alone. Apar t from t he diff erence in \nexacerbations, t here were only small diff erences betw een out comes when comparing ICS \nplus SABA as needed wit h as-needed AIR, and t he committ ee did not assess t hese as \nclinically impor tant. Ho wever, the evidence sho wed that use of ICS ( either as-needed AIR \nor regular lo w-dose ICS plus SABA as needed) pr oduced consist ently bett er out comes \nthan SABA alone. \nHealt h economic data sho wed that tr eatment wit h as-needed AIR was cheaper t han \nregular ICS plus SABA as needed. The committ ee therefore concluded t hat combination \ninhalers used as needed should be t he pr eferred tr eatment in newly diagnosed ast hma in \nadult s. Ho wever, there were concerns about t he minority of people wit h ast hma in whom \nthe diagnosis is first made because of an acut e attack. In t hese par ticularly sympt omatic \npeople, t he committ ee agr eed on saf ety gr ounds t hat initial tr eatment should be giv en \nregularly and r ecommended star ting t he lo w-dose MART (maint enance and r eliever \ntherap y) regimen. \nHow the r ecommenda tions mig ht affect practice \nMost people aged 12 and o ver wit h newly diagnosed ast hma ar e curr ently treated wit h \neither a SABA alone or wit h regular ICS plus SABA as needed. The new r ecommendations \nrepresent a significant change in practice. The use of combination inhalers is mor e \nexpensiv e than SABA alone, but cheaper t han r egular ICS plus SABA as needed. Ther efore, \nthe cost impact will v ary depending on t he pr edominant f orm of tr eatment in each general \npractice. Ho wever, there should be futur e savings fr om a r eduction in se vere ast hma", "1.12.3 Advise using t he following medicines as normal during pr egnancy: \n\u2022 shor t-acting and long-acting beta 2 agonist s \n\u2022 inhaled cor ticost eroids \n\u2022 oral t heoph yllines. [BTS/SIGN 2019] \n1.12.4 Offer oral cor ticost eroids during pr egnancy if needed t o treat e xacerbations of \nasthma. Advise t hat t he benefit s of tr eatment wit h oral cor ticost eroids outw eigh \nthe risks. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.12.5 If leuk otriene r ecept or antagonist s or long-acting muscarinic r ecept or antagonist s \nare needed t o achie ve ast hma contr ol, they should not be st opped during \npregnancy . [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \nBreastfeeding \n1.12.6 Use medicines as normal when br eastf eeding in line wit h recommendations in t he \nBNF. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 28 of\n64 1.13 A sthma in ado lescents \nFor guidance on transitioning t o adult ser vices, see t he NICE guideline on transition fr om \nchildr en's t o adult s' ser vices f or young people using healt h or social car e ser vices  and t he \nScottish Parliament Inf ormation Centr e briefing on transitions of y oung people wit h ser vice \nand car e needs betw een child and adult ser vices in Scot land. \n1.13.1 Discuss futur e car eer choices wit h adolescent s wit h ast hma and highlight \noccupations t hat might incr ease susceptibility t o work-related ast hma sympt oms. \n[BTS/SIGN 2019] \n1.13.2 Ask adolescent s wit h ast hma if t hey vape or smok e and encourage t hem t o stop. \nIf they smok e, giv e them advice and signpost t hem t o local NHS st op smoking \nservices. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.13.3 Ask about f actors t hat ma y affect a person's use of t heir inhaler de vice in r eal lif e \nsettings, such as school and social situations. [BTS/SIGN 2019] \n1.14 Self -manag emen t \n1.14.1 For adult s, young people and childr en aged 5 and o ver wit h a diagnosis of ast hma \n(and t heir f amilies or car ers, if appr opriat e): \n\u2022 Offer an ast hma self -management pr ogramme, comprising a document ed \npersonalised action plan and education. In adult s, they ma y be based on \nsympt oms or peak e xpirat ory flow (or bot h); sympt om-based plans ar e \nusually pr eferred for childr en. \n\u2022 Explain t hat t here are things t hat can trigger ast hma sympt oms and \nexacerbations, including indoor and out door pollution. Include in t he \npersonalised action plan appr oaches f or minimising e xposur e to air pollution \nand an y other personal triggers. F or mor e guidance on ho w to minimise \nexposur e and t he eff ect of air pollution on healt h, see t he recommendations \non: \n\uff0d vulnerable gr oups in t he NICE guideline on air pollution: out door air \nquality and healt h Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 29 of\n64 \uff0d people wit h ast hma, ot her r espirat ory conditions or car diovascular \nconditions in t he NICE guideline on indoor air quality at home , and \n\u2022 smoking in t he NICE guideline on t obacco . [NICE 2017 , amended 2021; BTS/\nSIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.14.2 Review t he cont ent of t he personalised action plan, and check t hat t he person \nunderstands it, at t he following: \n\u2022 hospital admission, including in vir tual war ds \n\u2022 acute consultations in primar y car e or emer gency depar tment \n\u2022 annual r eviews. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.14.3 Consider an ast hma self -management pr ogramme, comprising a writt en \npersonalised action plan (including appr oaches t o minimising e xposur e to indoor \nand out door air pollution) and education, f or the families or car ers of childr en \nunder 5 wit h suspect ed or confirmed ast hma. [NICE 2017 , amended NICE 2021] \n1.14.4 For adult s (aged 17 and o ver) who ar e using an inhaled cor ticost eroid (ICS) in a \nsingle inhaler , offer an incr eased dose of ICS f or 7 da ys, wit hin a self -\nmanagement pr ogramme, when ast hma contr ol det eriorat es. Clearly out line in t he \nperson's ast hma action plan ho w and when t o do t his, and what t o do if \nsympt oms do not impr ove. \nWhen incr easing ICS tr eatment: \n\u2022 consider quadrupling t he regular ICS dose \n\u2022 do not e xceed t he maximum licensed daily dose. [NICE 2017] \n1.14.5 Include advice in self -management pr ogrammes on contacting a healt hcare \nprofessional f or a r eview if ast hma contr ol det eriorat es (see t he \nrecommendations on monit oring ast hma contr ol). [NICE 2020 , amended BTS/\nNICE/SIGN 202 4] \n1.14.6 When implementing self -management int erventions in primar y car e, tak e into"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided aligns perfectly with the reference answer, stating that digital inhalers are not recommended for routine use in asthma management by the NHS. The response also adds additional context regarding the committee's conclusions on cost-effectiveness and the potential value of digital inhalers for selected individuals, which supports the accuracy and factual nature of the statement. Based on the score rubric, the response is completely correct, accurate, and factual."}, {"question": "What FeNO level indicates a diagnosis of asthma in children?", "generated_answer": "According to the context, a diagnosis of asthma in children is indicated by an FeNO level of 35 ppb or more.", "true_answer": "35 ppb or more.", "relevant_docs": ["SIGN 202 4] \nChildr en ag ed 5 to 16 \nSee also algorit hm B f or a summar y of objectiv e tests for diagnosing ast hma in childr en \naged 5 t o 16 wit h a hist ory suggesting ast hma. \n1.2.5 Measur e the FeNO le vel in childr en wit h a hist ory suggestiv e of ast hma. Diagnose \nasthma if t he FeNO le vel is 35  ppb or mor e. [BTS/NICE/SIGN 202 4] \n1.2.6 If the FeNO level is not raised, or if F eNO t esting is not a vailable, measur e BDR \nwith spir ometr y. Diagnose ast hma if t he FEV 1 increase is 12% or mor e from \nbaseline ( or if t he FEV 1 increase is 10% or mor e of t he pr edict ed normal FEV 1). \n[BTS/NICE/SIGN 202 4] \n1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \nDiagnose ast hma if PEF v ariability ( expressed as amplitude per centage mean) is \n20% or mor e. [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 11 of\n64 1.2.8 If asthma is not confirmed b y FeNO, BDR or PEF v ariability but still suspect ed on \nclinical gr ounds, eit her per form skin prick t esting  to house dust mit e or measur e \ntotal IgE le vel and blood eosinophil count. \n\u2022 Exclude ast hma if t here is no e vidence of sensitisation t o house dust mit e on \nskin prick t esting or if t he total serum IgE is not raised. \n\u2022 Diagnose ast hma if t here is e vidence of sensitisation or a raised t otal IgE \nlevel and t he eosinophil count is mor e than 0 .5 x 109\n per litr e. [BTS/NICE/\nSIGN 202 4] \n1.2.9 If there is still doubt about t he diagnosis, r efer to a paediatric specialist f or a \nsecond opinion, including consideration of a br onchial challenge t est. [BTS/NICE/\nSIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 12 of\n64 For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on objectiv e tests for \ndiagnosing ast hma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory \nsuggestiv e of ast hma. \nFull details of t he evidence and t he committ ee's discussion ar e in: \n\u2022 evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \nasthma \n\u2022 evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \npeople suspect ed of ast hma \n\u2022 evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or \nthe diagnosis of ast hma \n\u2022 evidence r eview  D: accuracy of skin prick t est in childr en for the diagnosis of \nasthma \n\u2022 evidence r eview E: diagnostic t est accuracy of IgE in childr en \n\u2022 evidence r eview  F: diagnostic accuracy of fractional e xhaled nitric o xide (F eNO) \nmeasur es \n\u2022 evidence r eview  G: diagnostic accuracy of eosinophil blood count measur es in t he \ndiagnosis of ast hma \n\u2022 evidence r eview  H: br onchial challenge wit h histamine and met hacholine f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  I: bronchial challenge t est wit h mannit ol \n\u2022 evidence r eview  J: bronchial challenge t esting in r esponse t o exercise f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 13 of\n64 1.3 D iagnosing asthma in childr en under 5 \nDiagnosis is har d in t his age gr oup because it is difficult t o do t he tests and t here are no \ngood r eference standar ds. \n1.3.1 For childr en under 5 wit h suspect ed ast hma, tr eat wit h inhaled cor ticost eroids in \nline wit h the recommendations on medicines f or initial management in childr en \nunder  5, and r eview t he child on a r egular basis. If t hey still ha ve sympt oms when \nthey reach 5 y ears, att empt objectiv e tests (see t he section on objectiv e tests for \ndiagnosing ast hma in adult s, young people and childr en aged 5 t o 16). [NICE \n2017] \n1.3.2 If a child is unable t o per form objectiv e tests when t hey are aged 5: \n\u2022 try doing t he tests again e very 6 to 12 mont hs until satisf actory result s are \nobtained \n\u2022 refer for specialist assessment if t he child's ast hma is not r esponding t o \ntreatment. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.3.3 Refer to a specialist r espirat ory paediatrician an y preschool child wit h an \nadmission t o hospital, or 2 or mor e admissions t o an emer gency depar tment, wit h \nwheez e in a 12-mont h period. [BTS/NICE/SIGN 202 4] \n1.4 D iagnosing oc cupa tional asthma", "included in a personalised action plan because pollution can trigger and e xacerbat e \nasthma. \nFebruar y 2020:  NICE r eview ed the evidence on incr easing t he dose of inhaled \ncorticost eroids wit hin a self -management pr ogramme in childr en and y oung people wit h \nasthma and r emoved a r ecommendation. A new r ecommendation on self -management in \nchildr en and y oung people was made. This r ecommendation is mark ed [2020 , amended \nBTS/NICE/SIGN 202 4]. \nBTS ISBN: 9 78-1-917 619-01-1 \nNICE ISBN: 9 78-1-47 31-6612- 7 \nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 64 of\n64"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "Feedback: The response provided is completely correct, accurate, and factual. It matches the reference answer by stating that an FeNO level of 35 ppb or more indicates a diagnosis of asthma in children."}, {"question": "How many asthma deaths were there in the UK in 2018?", "generated_answer": "There is no information provided in the context about the number of asthma deaths in the UK in 2018. The context only discusses guidelines for diagnosing, monitoring, and managing asthma, and does not include any data or statistics about asthma deaths.", "true_answer": "More than 1,400 asthma deaths.", "relevant_docs": ["This guideline is t he basis of QS181 and QS25 . \nThis guideline should be r ead in conjunction wit h NG2 44. \nOverview \nThis guideline co vers diagnosing, monit oring and managing ast hma in adult s, young \npeople and childr en. It aims t o impr ove the accuracy of diagnosis, help people t o contr ol \ntheir ast hma and r educe t he risk of ast hma attacks. It does not co ver managing se vere \nasthma or acut e ast hma attacks. \nLast r eviewed: 27 No vember 202 4 \nThis is a new collaborativ e guideline de veloped joint ly by the British Thoracic Society \n(BTS), National Institut e for Healt h and Car e Excellence (NICE) and Scottish Int ercollegiat e \nGuidelines Netw ork (SIGN). \nIt updat es and r eplaces NICE guideline 80 (published No vember 2017) and par ts of BTS/\nSIGN British guideline SIGN 158 (published July 2019).  It also updat es and r eplaces NICE \ntechnology appraisal guidance 10 , 38,131 and 138 , and NICE diagnostics guidance 12. \nWe review ed the evidence and made new or updat ed recommendations on diagnosis, \ntreatment and monit oring. W e also updat ed some r ecommendations wit hout an e vidence \nreview . For full details see updat e information . \nNext review: This guidance will be r eview ed if t here is new e vidence t hat is lik ely to \nchange t he recommendations. \nBTS, NICE and SIGN ha ve developed an ast hma pat hway, which brings t oget her \nrecommendations on diagnosing, monit oring and managing ast hma in adult s, young \npeople and childr en. It aims t o impr ove the accuracy of diagnosis, help people t o contr ol \ntheir ast hma and r educe t he risk of ast hma attacks. It also co vers managing difficult and \nsevere ast hma and acut e ast hma attacks. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 5 of\n64 Who is i t for? \n\u2022 Healt hcare professionals in primar y car e and t he community , secondar y car e and \ntertiary ast hma ser vices \n\u2022 Commissioners and pr oviders \n\u2022 People wit h suspect ed or diagnosed ast hma, t heir f amilies and car ers Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 6 of\n64 Recommenda tions Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 7 of\n64 People ha ve the right t o be in volved in discussions and mak e informed decisions \nabout t heir car e, as described in NICE's inf ormation on making decisions about y our \ncare. Information about decision making is also a vailable fr om Realistic medicine . \nMaking decisions using NICE guidelines  and Using SIGN guidelines  explains ho w we \nuse w ords to sho w the str engt h (or cer tainty) of our r ecommendations, inf ormation \nabout pr escribing medicines (including off -label use), pr ofessional guidelines, \nstandar ds and laws (including on consent and mental capacity), and saf eguar ding. \nIn this guideline, t he NHS r efers t o NHS England and NHS Scot land unless stat ed \notherwise. The r ecommendations ar e for all age gr oups unless indicat ed ot herwise in \nthe heading of t he guideline section. \nHealt h professionals should f ollow these NICE guidelines f or people deliv ering car e: \n\u2022 Shar ed decision making \n\u2022 Medicines adher ence \n\u2022 Multimorbidity . \nIn addition, healt h professionals in England should f ollow these NICE guidelines f or \npeople deliv ering car e: \n\u2022 Medicines optimisation \n\u2022 Patient e xperience in adult NHS ser vices \n\u2022 Babies, childr en and y oung people's e xperience of healt hcare \n\u2022 Decision making and mental capacity \nIn addition, healt h professionals in Scot land should f ollow Scottish Go vernment \nguidance f or people deliv ering car e: \n\u2022 Realistic Medicine \n\u2022 Healt h and social car e standar ds Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 8 of\n64 \u2022 Mental healt h legislation and guidance \n\u2022 Getting it right f or every child . \n1.1 Initial clinic al assessmen t \nClinic al histor y \n1.1.1 Obtain a structur ed clinical hist ory in people wit h suspect ed ast hma. Specifically , \ncheck f or: \n\u2022 repor ted wheez e, noisy br eathing, cough, br eathlessness or chest tightness, \nand an y variation (f or example, w orse during t he night or early morning, or \nseasonal) in t hese sympt oms \n\u2022 any triggers t hat mak e sympt oms w orse \n\u2022 a personal or f amily hist ory of ast hma or aller gic rhinitis", "included in a personalised action plan because pollution can trigger and e xacerbat e \nasthma. \nFebruar y 2020:  NICE r eview ed the evidence on incr easing t he dose of inhaled \ncorticost eroids wit hin a self -management pr ogramme in childr en and y oung people wit h \nasthma and r emoved a r ecommendation. A new r ecommendation on self -management in \nchildr en and y oung people was made. This r ecommendation is mark ed [2020 , amended \nBTS/NICE/SIGN 202 4]. \nBTS ISBN: 9 78-1-917 619-01-1 \nNICE ISBN: 9 78-1-47 31-6612- 7 \nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 64 of\n64"], "eval_score_GPT4": "1", "eval_feedback_GPT4": "Feedback: The response provided does not answer the question regarding the number of asthma deaths in the UK in 2018. Instead, it discusses the lack of information in the context about asthma deaths and focuses on guidelines for diagnosing, monitoring, and managing asthma without providing any data or statistics. According to the score rubric, the response should be evaluated as completely incorrect, inaccurate, and not factual since it does not provide the requested number of asthma deaths."}, {"question": "What level of FeNO is considered reasonably specific for asthma in children with a suggestive history?", "generated_answer": "According to the context, a FeNO level of 35 ppb or more is considered diagnostic for asthma in children with a suggestive history.", "true_answer": "35 ppb or more.", "relevant_docs": ["SIGN 202 4] \nChildr en ag ed 5 to 16 \nSee also algorit hm B f or a summar y of objectiv e tests for diagnosing ast hma in childr en \naged 5 t o 16 wit h a hist ory suggesting ast hma. \n1.2.5 Measur e the FeNO le vel in childr en wit h a hist ory suggestiv e of ast hma. Diagnose \nasthma if t he FeNO le vel is 35  ppb or mor e. [BTS/NICE/SIGN 202 4] \n1.2.6 If the FeNO level is not raised, or if F eNO t esting is not a vailable, measur e BDR \nwith spir ometr y. Diagnose ast hma if t he FEV 1 increase is 12% or mor e from \nbaseline ( or if t he FEV 1 increase is 10% or mor e of t he pr edict ed normal FEV 1). \n[BTS/NICE/SIGN 202 4] \n1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \nDiagnose ast hma if PEF v ariability ( expressed as amplitude per centage mean) is \n20% or mor e. [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 11 of\n64 1.2.8 If asthma is not confirmed b y FeNO, BDR or PEF v ariability but still suspect ed on \nclinical gr ounds, eit her per form skin prick t esting  to house dust mit e or measur e \ntotal IgE le vel and blood eosinophil count. \n\u2022 Exclude ast hma if t here is no e vidence of sensitisation t o house dust mit e on \nskin prick t esting or if t he total serum IgE is not raised. \n\u2022 Diagnose ast hma if t here is e vidence of sensitisation or a raised t otal IgE \nlevel and t he eosinophil count is mor e than 0 .5 x 109\n per litr e. [BTS/NICE/\nSIGN 202 4] \n1.2.9 If there is still doubt about t he diagnosis, r efer to a paediatric specialist f or a \nsecond opinion, including consideration of a br onchial challenge t est. [BTS/NICE/\nSIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 12 of\n64 For a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on objectiv e tests for \ndiagnosing ast hma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory \nsuggestiv e of ast hma. \nFull details of t he evidence and t he committ ee's discussion ar e in: \n\u2022 evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \nasthma \n\u2022 evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \npeople suspect ed of ast hma \n\u2022 evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or \nthe diagnosis of ast hma \n\u2022 evidence r eview  D: accuracy of skin prick t est in childr en for the diagnosis of \nasthma \n\u2022 evidence r eview E: diagnostic t est accuracy of IgE in childr en \n\u2022 evidence r eview  F: diagnostic accuracy of fractional e xhaled nitric o xide (F eNO) \nmeasur es \n\u2022 evidence r eview  G: diagnostic accuracy of eosinophil blood count measur es in t he \ndiagnosis of ast hma \n\u2022 evidence r eview  H: br onchial challenge wit h histamine and met hacholine f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  I: bronchial challenge t est wit h mannit ol \n\u2022 evidence r eview  J: bronchial challenge t esting in r esponse t o exercise f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 13 of\n64 1.3 D iagnosing asthma in childr en under 5 \nDiagnosis is har d in t his age gr oup because it is difficult t o do t he tests and t here are no \ngood r eference standar ds. \n1.3.1 For childr en under 5 wit h suspect ed ast hma, tr eat wit h inhaled cor ticost eroids in \nline wit h the recommendations on medicines f or initial management in childr en \nunder  5, and r eview t he child on a r egular basis. If t hey still ha ve sympt oms when \nthey reach 5 y ears, att empt objectiv e tests (see t he section on objectiv e tests for \ndiagnosing ast hma in adult s, young people and childr en aged 5 t o 16). [NICE \n2017] \n1.3.2 If a child is unable t o per form objectiv e tests when t hey are aged 5: \n\u2022 try doing t he tests again e very 6 to 12 mont hs until satisf actory result s are \nobtained \n\u2022 refer for specialist assessment if t he child's ast hma is not r esponding t o \ntreatment. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.3.3 Refer to a specialist r espirat ory paediatrician an y preschool child wit h an \nadmission t o hospital, or 2 or mor e admissions t o an emer gency depar tment, wit h \nwheez e in a 12-mont h period. [BTS/NICE/SIGN 202 4] \n1.4 D iagnosing oc cupa tional asthma", "included in a personalised action plan because pollution can trigger and e xacerbat e \nasthma. \nFebruar y 2020:  NICE r eview ed the evidence on incr easing t he dose of inhaled \ncorticost eroids wit hin a self -management pr ogramme in childr en and y oung people wit h \nasthma and r emoved a r ecommendation. A new r ecommendation on self -management in \nchildr en and y oung people was made. This r ecommendation is mark ed [2020 , amended \nBTS/NICE/SIGN 202 4]. \nBTS ISBN: 9 78-1-917 619-01-1 \nNICE ISBN: 9 78-1-47 31-6612- 7 \nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 64 of\n64"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided correctly identifies that a FeNO level of 35 ppb or more is considered diagnostic for asthma in children with a suggestive history. This matches the reference answer, which also states \"35 ppb or more.\" Therefore, the response is completely correct, accurate, and factual."}]